The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Clinical Trial ID NCT03240328

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03240328

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.	N Engl J Med	2013	10.63
2	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.	Blood	2011	8.26
3	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.	Lancet	2014	5.42
4	Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides.	Cell	1991	2.45
5	Design and development of therapies using chimeric antigen receptor-expressing T cells.	Immunol Rev	2014	1.81
6	Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.	Virology	2013	0.88
7	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.	Mol Ther	2015	0.88
8	Chimeric antigen receptor-modified T cells in CLL.	N Engl J Med	2011	0.86
9	Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.	Stem Cells	2014	0.85
10	Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.	J Virol	2015	0.84
11	A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells.	J Med Primatol	2014	0.78
12	Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.	N Engl J Med	2016	0.76